26
Jul
2018
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.